Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now displays a 403 Forbidden error instead of showing the study record content, indicating a permissions issue on the page.SummaryDifference20%

- Check28 days agoChange DetectedThe page revision identifier was updated from v3.6.6 to v3.7.0, indicating a refresh of the page content or layout without changing the underlying study information.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page footer now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5, indicating a new build release.SummaryDifference0.1%

- Check56 days agoChange DetectedA citation for the Maveropepimut-S, pembrolizumab and low-dose cyclophosphamide paper was added to the Publications section, replacing the previous 'Online ahead of print' entry with the finalized Nat Commun article details (authors, title, journal, date, volume, and DOI).SummaryDifference0.1%

- Check64 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a new page release. This update reflects backend/frontend maintenance and does not modify study details or how the page is used by visitors.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.